Viewpoint discusses the 340B Drug Pricing Program's history and calls for congressional action to support safety-net providers.
This Viewpoint presents the history of the Health Resources & Services Administration (HRSA) 340B Drug Pricing Program and 340B Rebate Model Pilot Program, summarizes their controversies and limitations, and calls for action by Congress and HRSA to address these issues and strengthen support for safety-net hospitals and clinics.
No takes yet. Share an insight, caveat, or question.
Knox et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: